How were new medicines discovered?
The DOI matches its Crossref record; 171 of the 173 references it cites were found in a registry or an index.
Abstract
Preclinical strategies that are used to identify potential drug candidates include target-based screening, phenotypic screening, modification of natural substances and biologic-based approaches. To investigate whether some strategies have been more successful than others in the discovery of new drugs, we analysed the discovery strategies and the molecular mechanism of action (MMOA) for new molecular entities and new biologics that were approved by the US Food and Drug Administration between 1999 and 2008. Out of the 259 agents that were approved, 75 were first-in-class drugs with new MMOAs, and out of these, 50 (67%) were small molecules and 25 (33%) were biologics. The results also show that the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches - with 28 and 17 of these drugs coming from the two approaches, respectively - in an era in which the major focus was on target-based approaches. We postulate that a target-centric approach for first-in-class drugs, without consideration of an optimal MMOA, may contribute to the current high attrition rates and low productivity in pharmaceutical research and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There are two main advantages of the phenotypic screening method for identifying covalent PPI inhibitors. Firstly, this technique identifies cell-active compounds directly. Secondly, the biological target does not have to be known before screening [81].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [81]
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., & Wang, X. (1997) · Cell · doi:10.1016/s0092-8674(00)80434-1 · Cited by 7,289
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Research works printed but not linked: 3
- Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
- Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
- Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
Cited by
Items 501–600 of 1,000
Chen, H., Engkvist, O., Blomberg, N., & Li, J. (2011) · MedChemComm · doi:10.1039/c2md00238h · Cited by 40
Chemical biology approaches to target validation in cancer
Blagg, J., & Workman, P. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.007 · Cited by 41
Memar, B., Jamili, S., Shahbazzadeh, D., & Bagheri, K. P. (2016) · Toxicon · doi:10.1016/j.toxicon.2016.02.004 · Cited by 38
Reduced neuronal size and mTOR pathway activity in the Mecp2 A140V Rett syndrome mouse model
Rangasamy, S., Olfers, S., Gerald, B., Hilbert, A., Svejda, S., & Narayanan, V. (2016) · F1000Research · doi:10.12688/f1000research.8156.1 · Cited by 44
High-throughput flow cytometry for drug discovery: principles, applications, and case studies
Ding, M., Kaspersson, K., Murray, D., & Bardelle, C. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.005 · Cited by 38
Glucose consumption assay discovers coptisine with beneficial effect on diabetic mice
Shi, L., Jia, W., Zhang, L., Xu, C., Chen, X., Yin, L., Wang, N., Fang, L., Qiang, G., Yang, X., et al. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172523 · Cited by 38
Chagas Disease: Current View of an Ancient and Global Chemotherapy Challenge
Martín‐Escolano, J., Medina‐Carmona, E., & Martín‐Escolano, R. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00353 · Cited by 39
Andriani, P., & Kamińska, R. (2020) · Research Policy · doi:10.1016/j.respol.2020.104171 · Cited by 41
Hou, B., Zhao, Y., Ma, P., Xu, C., He, P., Yang, X., Zhang, L., Qiang, G., & Du, G. (2020) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(20)60022-x · Cited by 42
Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Roy, S., Dhaneshwar, S. S., & Bhasin, B. (2021) · Current Drug Research Reviews · doi:10.2174/2589977513666210211163711 · Cited by 42
Drug repurposing: Iron in the fire for older drugs
Sonaye, H. V., Sheikh, R. Y., & Doifode, C. A. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111638 · Cited by 39
Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists
Deng, H., Hu, H., Ling, S., Ferrie, A. M., & Ye, F. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2003058 · Cited by 38
The evolution of drug discovery: from phenotypes to targets, and back
Al‐Ali, H. (2016) · MedChemComm · doi:10.1039/c6md00129g · Cited by 46
Combinatorial prediction of therapeutic perturbations using causally inspired neural networks
Gonzalez, G., Lin, X., Herath, I. S., Veselkov, K., Bronstein, M. M., & Žitnik, M. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01481-x · Cited by 60
An update of novel screening methods for GPCR in drug discovery
Chen, L., Jin, L., & Zhou, N. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.699036 · Cited by 42
Post-Ugi Cascade Transformations for Accessing Diverse Chromenopyrrole Collections
Srinivasulu, V., Sieburth, S. M., El‐Awady, R., Kariem, N. M., Tarazi, H., O’Connor, M. J., & Al‐Tel, T. H. (2018) · Organic Letters · doi:10.1021/acs.orglett.7b03986 · Cited by 37
Liu, D., Meng, S., Xiang, Z., He, N., & Yang, G. (2019) · Phytochemistry · doi:10.1016/j.phytochem.2019.03.026 · Cited by 37
Lam, C. K., & Wu, J. C. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314695 · Cited by 38
Cornelissen, F. W., Cik, M., & Gustin, E. M. (2012) · SLAS DISCOVERY · doi:10.1177/1087057111432885 · Cited by 40
Tang, X., & Du, J. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.139750 · Cited by 37
Drug Repositioning: Playing Dirty to Kill Pain
Bastos, L. F. S., & Coelho, M. M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0128-0 · Cited by 38
Peppard, J., Rugg, C. A., Smicker, M. A., Dureuil, C., Ronan, B., Flamand, O., Durand, L., & Pasquier, B. (2014) · Current Chemical Genomics · doi:10.2174/2213988501408010003 · Cited by 36
Hizukuri, Y., Sawada, R., & Yamanishi, Y. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0158-1 · Cited by 37
In Vitro and in Vivo Anti- Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives
Moreno‐Viguri, E., Jiménez-Montes, C., Martín‐Escolano, R., Santivañez‐Veliz, M., Martín‐Montes, Á., Azqueta, A., Jiménez‐López, M. C., Zamora-Ledesma, S., Cirauqui, N., de Ceráin, A. L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00784 · Cited by 36
Lapchak, P. A., Boitano, P. D., de Couto, G., & Marbán, E. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.06.007 · Cited by 37
The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery
Friese, A., Ursu, A., Hochheimer, A., Schöler, H. R., Waldmann, H., & Bruder, J. M. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.05.007 · Cited by 37
Drug discovery for primary amebic meningoencephalitis: from screen to identification of leads
Debnath, A. (2021) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1882302 · Cited by 36
Synthesis of Complex and Diverse Compounds through Ring Distortion of Abietic Acid
Rafferty, R. J., Hicklin, R. W., Maloof, K. A., & Hergenrother, P. J. (2013) · Angewandte Chemie · doi:10.1002/ange.201308743 · Cited by 36
Perspective on the Discovery and Scientific Impact of p38 MAP Kinase
Young, P. R. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113497401 · Cited by 37
Human Disease and Drug Pharmacology, Complex as Real Life
Viayna, E., Sola, I., Pietro, O. D., & Muñoz‐Torrero, D. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130002 · Cited by 39
Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets
Vasaikar, S. V., Bhatia, P., Bhatia, P. G., & Yaiw, K.-C. (2016) · Biomedicines · doi:10.3390/biomedicines4040027 · Cited by 38
Human Genomics and Drug Development
Schmidt, A. F., Hingorani, A. D., & Finan, C. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039230 · Cited by 41
Zhang, L., Chen, C. Y., Fu, J., Lilley, B. N., Berlinicke, C. A., Hansen, B. S., Ding, D., Wang, G., Wang, T., Shou, D., et al. (2021) · eLife · doi:10.7554/elife.57245 · Cited by 35
RxRx1: A Dataset for Evaluating Experimental Batch Correction Methods
Sypetkowski, M., Rezanejad, M., Saberian, S., Kraus, O. Z., Urbanik, J., Taylor, J., Mabey, B., Victors, M. L., Yosinski, J., Sereshkeh, A. R., et al. (2023) · IEEE/CVF Conference on Computer Vision and Pattern Recognition Workshops (CVPRW) · doi:10.1109/cvprw59228.2023.00451 · Cited by 75
Patient-Specific Induced Pluripotent Stem Cells for Disease Modeling and Phenotypic Drug Discovery
Tang, S., Xie, M., Cao, N., & Ding, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00789 · Cited by 40
An Alternative Approach To Drug Discovery For Alzheimer’s Disease Dementia
Schubert, D. A., & Maher, P. A. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.109 · Cited by 37
Principles of dynamical modularity in biological regulatory networks
Deritei, D., Aird, W. C., Ercsey-Ravasz, M., & Regan, E. R. (2016) · Scientific Reports · doi:10.1038/srep21957 · Cited by 42
Schidlitzki, A., Bascuñana, P., Srivastava, P. K., Welzel, L., Twele, F., Töllner, K., Käufer, C., Gericke, B., Feleke, R., Meier, M., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104664 · Cited by 39
DRUG-seq Provides Unbiased Biological Activity Readouts for Neuroscience Drug Discovery
Li, J., Ho, D. J., Hénault, M., Yang, C., Neri, M., Ge, R., Renner, S., Mansur, L., Lindeman, A., Kelly, B., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00920 · Cited by 38
Drug repositioning: A bibliometric analysis
Sun, G., Dong, D., Dong, Z., Zhang, Q., Fang, H., Wang, C., Zhang, S., Wu, S., Dong, Y., & Wan, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.974849 · Cited by 38
CNS Target Identification and Validation: Avoiding the Valley of Death or Naive Optimism?
Hutson, P. H., Clark, J. A., & Cross, A. J. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104624 · Cited by 40
Ljungars, A., Svensson, C., Carlsson, A., Birgersson, E., Tornberg, U., Frendéus, B., Ohlin, M., & Mattsson, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00847 · Cited by 37
Three-Dimensional Cell Cultures in Drug Discovery and Development
Ye, F., & Eglen, R. M. (2017) · SLAS DISCOVERY · doi:10.1177/2472555217696795 · Cited by 57
An, R., Merrill, D., Avramova, L., Sturgis, J., Tsiper, M., Robinson, J. P., Turek, J., & Nolte, D. D. (2014) · SLAS Discovery · doi:10.1177/1087057113516674 · Cited by 35
The opportunities of mining historical and collective data in drug discovery
Wassermann, A. M., Lounkine, E., Davies, J. W., Glick, M., & Camargo, L. M. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2014.11.004 · Cited by 34
GlyNet: a multi-task neural network for predicting protein–glycan interactions
Carpenter, E. J., Seth, S., Yue, N., Greiner, R., & Derda, R. (2022) · Chemical Science · doi:10.1039/d1sc05681f · Cited by 38
Dančík, V., Carrel, H., Bodycombe, N. E., Seiler, K. P., Fomina-Yadlin, D., Kubicek, S. T., Hartwell, K., Shamji, A. F., Wagner, B. K., & Clemons, P. A. (2014) · SLAS Discovery · doi:10.1177/1087057113520226 · Cited by 34
Target mRNA inhibition by oligonucleotide drugs in man
Lightfoot, H. L., & Hall, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks861 · Cited by 36
Translational paradigms in pharmacology and drug discovery
Mullane, K., Winquist, R. J., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.019 · Cited by 35
Effects of Lovastatin on MDA-MB-231 Breast Cancer Cells: An Antibody Microarray Analysis
Yang, T., Yao, H., He, G., Song, L., Liu, N., Wang, Y., Yang, Y., Keller, E. T., & Deng, X. (2015) · Journal of Cancer · doi:10.7150/jca.13414 · Cited by 35
Meena, D. R., Maiti, B., & Chanda, K. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.10.109 · Cited by 35
Tong, J. X., Chandramohanadas, R., & Tan, K. S. W. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02031-17 · Cited by 34
Drug discovery strategies for acute radiation syndrome
Singh, V. K., Seed, T. M., & Olabisi, A. O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1604674 · Cited by 38
Campbell, A., Mohl, J. E., Gutiérrez, D. A., Varela-Ramírez, A., & Boland, T. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00082 · Cited by 36
Colorectal cancer drug target prediction using ontology-based inference and network analysis
Tao, C., Sun, J., Zheng, W. J., Chen, J., & Xu, H. (2015) · Database · doi:10.1093/database/bav015 · Cited by 34
Pfeiffer, E. R., Vega, R., McDonough, P. M., Price, J. H., & Whittaker, R. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.04.007 · Cited by 35
Kinase-Independent Small-Molecule Inhibition of JAK-STAT Signaling
Chou, D. H., Vetere, A., Choudhary, A., Scully, S. S., Schenone, M., Tang, A. J., Gomez, R. C., Burns, S. M., Lundh, M., Vital, T., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b04284 · Cited by 34
α-Cedrene protects rodents from high-fat diet-induced adiposity via adenylyl cyclase 3
Tong, T., Yu, R., & Park, T. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0176-0 · Cited by 34
Exaptation, serendipity and aging
Andriani, P. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.01.001 · Cited by 33
Practical and low cost whole-organism motility assay: A step-by-step protocol
Preston, S., Jabbar, A., Nowell, C. J., Joachim, A., Ruttkowski, B., Cardno, T. S., Hofmann, A., & Gasser, R. B. (2015) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2015.08.005 · Cited by 34
System-based drug discovery within the human kinome
Bamborough, P. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.724056 · Cited by 36
Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family
Morse, M., Sun, H., Tran, E., Levenson, R. G., & Ye, F. (2013) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-14-17 · Cited by 34
Advanced Molecular Dynamics Simulation Methods for Kinase Drug Discovery
Aci‐Sèche, S., Ziada, S., Braka, A., Arora, R., & Bonnet, P. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc.16.9 · Cited by 37
Gerüstdiversitätsbasierte Synthese und ihre Anwendung bei der Sonden‐ und Wirkstoffsuche
García-Castro, M., Zimmermann, S., Sankar, M. G., & Kumar, K. (2016) · Angewandte Chemie · doi:10.1002/ange.201508818 · Cited by 33
Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery
Cruz‐Monteagudo, M., Schürer, S. C., Tejera, E., Pérez‐Castillo, Y., Medina‐Franco, J. L., Sánchez‐Rodríguez, A., & Borges, F. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.02.004 · Cited by 34
Holenz, J., & Stoy, P. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.001 · Cited by 35
Screening in serum-derived medium reveals differential response to compounds targeting metabolism
Abbott, K. L., Ali, A., Casalena, D. E., Do, B. T., Ferreira, R., Cheah, J. H., Soule, C. K., Deik, A., Kunchok, T., Schmidt, D. R., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.08.007 · Cited by 38
Ye, J.-M., & Stanley, M. H. (2013) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3t60g · Cited by 34
Munoz, L., Kavanagh, M. E., Phoa, A., Heng, B., Dzamko, N. L., Chen, E.-J., Doddareddy, M. R., Guillemin, G. J., & Kassiou, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.03.003 · Cited by 35
Active Learning Strategies for Phenotypic Profiling of High-Content Screens
Smith, K., & Horváth, P. (2014) · SLAS DISCOVERY · doi:10.1177/1087057114527313 · Cited by 33
Zhou, W., Zhong, G., Fu, S., Xie, H., Chi, T., Li, L., Rao, X., Zeng, S., Xu, D., Wang, H., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00125 · Cited by 35
Zebrafish small molecule screens: Taking the phenotypic plunge
Williams, C. H., & Hong, C. C. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.09.001 · Cited by 41
Zebrafish as an in vivo model for sustainable chemical design
Noyes, P. D., Garcia, G. R., & Tanguay, R. L. (2016) · Green Chemistry · doi:10.1039/c6gc02061e · Cited by 35
Comparative pharmacokinetic profile of cyclosporine (CsA) with a decapeptide and a linear analogue
Price, D. A., Eng, H. F., Farley, K. A., Goetz, G. H., Huang, Y., Jiao, Z., Kalgutkar, A. S. S., Kablaoui, N. M., Khunte, B., Liras, S. I., et al. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob00096k · Cited by 33
Phenotypic chemical biology for predicting safety and efficacy
Berg, E. L. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.01.001 · Cited by 35
Bar, H., & Zweifach, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220942764 · Cited by 32
Cui, X., Li, X., Zheng, H., Su, Y., Zhang, S., Li, M., Hao, X., Zhang, S., Hu, Z., Xia, Z., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00799-8 · Cited by 41
HCS-3DX, a next-generation AI-driven automated 3D-oid high-content screening system
Diósdi, Á., Tóth, T., Harmati, M., Grexa, I., Schrettner, B., Hapek, N., Kovács, F., Kriston, A., Buzás, K., Pampaloni, F., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63955-5 · Cited by 40
Kuang, Y., Yuan, D., Zhang, Y., Kao, A., Du, X., & Xu, B. (2013) · RSC Advances · doi:10.1039/c3ra41523f · Cited by 32
Computational Profiling of Bioactive Compounds Using a Target-Dependent Composite Workflow
Meslamani, J. E., Bhajun, R., Martz, F., & Rognan, D. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400303n · Cited by 35
Development of High-Content Assays for Kidney Progenitor Cell Expansion in Transgenic Zebrafish
Sanker, S., Cirio, M. C., Vollmer, L. L., Goldberg, N. D., McDermott, L. A., Hukriede, N. A., & Vogt, A. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113495296 · Cited by 33
Handling the Hurdles on the Way to Anti-tuberculosis Drug Development
Dalberto, P. F., de Souza, E. V., Abbadi, B. L., Neves, C. E., Rambo, R. S., Ramos, A. S., Macchi, F. S., Machado, P., Bizarro, C. V., & Basso, L. A. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.586294 · Cited by 38
Mignani, S. M., Tripathi, V. D., Soam, D., Tripathi, R. P., Das, S., Singh, S., Gandikota, R., Laurent, R., Karpus, A. O., Caminade, A., et al. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00355 · Cited by 36
Jung, D., Junek, G. V., Park, J.-S., Kumashi, S., Wang, A. Y., Li, S., Grijalva, S. I., Fernandez, N., Cho, H. C., & Wang, H. (2021) · IEEE Journal of Solid-State Circuits · doi:10.1109/jssc.2021.3085571 · Cited by 34
FingerDTA: A Fingerprint-Embedding Framework for Drug-Target Binding Affinity Prediction
Zhu, X., Liu, J., Zhang, J., Yang, Z., Yang, F., & Zhang, X. (2022) · Big Data Mining and Analytics · doi:10.26599/bdma.2022.9020005 · Cited by 32
Affinity purification in target identification: the specificity challenge
Zheng, W., Li, G., & Li, X. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0635-2 · Cited by 34
Logic Modeling in Quantitative Systems Pharmacology
Traynard, P., Tobalina, L., Eduati, F., Calzone, L., & Sáez-Rodríguez, J. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12225 · Cited by 38
Yang, W., Padkjær, S. B., Wang, J., Sun, Z., Shan, B., Yang, L., Chen, H., Kang, L., Madsen, D., Li, X., et al. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.08.023 · Cited by 33
Representing high throughput expression profiles via perturbation barcodes reveals compound targets
Filzen, T. M., Kutchukian, P. S., Hermes, J. D., Li, J., & Tudor, M. (2017) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005335 · Cited by 31
“Phenotypic screening is considered by some to be a return to pharmacology’s roots (Swinney and Anthony 2011), and by others a new discipline, that will need to prove itself over the coming decades (Eder, Sedrani et al.”
Zhang, X., Lytovchenko, O., Lundström, S. L., Zubarev, R. A., & Gaetani, M. (2022) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4556 · Cited by 35
Ogasawara, D., Konrad, D. B., Tan, Z. Y., Carey, K. L., Luo, J., Won, S. J., Li, H., Carter, T. R., DeMeester, K. E., Njomen, E., et al. (2024) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.005 · Cited by 31
From yeast to patient neurons and back again: Powerful new discovery platforms
Tardiff, D. F., Khurana, V., Chung, C. Y., & Lindquist, S. L. (2014) · Movement Disorders · doi:10.1002/mds.25989 · Cited by 36
Discovery of neuroprotective compounds by machine learning approaches
Fang, J., Pang, X., Yan, R., Lian, W., Li, C., Wang, Q., Liu, A.-L., & Du, G.-H. (2016) · RSC Advances · doi:10.1039/c5ra23035g · Cited by 31
Krushkal, J., Negi, S., Yee, L. M., Evans, J. R., Grkovic, T., Palmisano, A., Fang, J., Sankaran, H., McShane, L. M., Zhao, Y., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12849 · Cited by 35
BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
Fiorentino, F. P., Marchesi, I., Schröder, C., Schmidt, R., Yokota, J., & Bagella, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249595 · Cited by 32
Paul, A., Anand, R., Karmakar, S. P., Rawat, S., Bairagi, N., & Chatterjee, S. (2021) · Scientific Reports · doi:10.1038/s41598-020-80561-1 · Cited by 33
High-content approaches to anthelmintic drug screening
Zamanian, M., & Chan, J. D. (2021) · Trends in Parasitology · doi:10.1016/j.pt.2021.05.004 · Cited by 36
Mind the Gaps: How Organization Design Shapes the Sourcing of Inventions
Eklund, J. C., & Kapoor, R. (2021) · Organization Science · doi:10.1287/orsc.2021.1483 · Cited by 37
Is Amyloid Binding Alcohol Dehydrogenase a Drug Target for Treating Alzheimer’s Disease?
Borger, E., Aitken, L., Du, H., Zhang, W., Gunn‐Moore, F. J., & Yan, S. S. D. (2013) · Current Alzheimer Research · doi:10.2174/1567205011310010004 · Cited by 36
Wu, J., Xiao, Y., Lin, M., Cai, H., Zhao, D., Li, Y., Luo, H., Tang, C., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115401 · Cited by 34
Metadata
- Authors
- Swinney, D. C., & Anthony, J.
- Corresponding author
- Swinney, David C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-06-24
- Volume
- 10
- Issue
- 7
- Pages
- 507-519
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2052214665
- Cited by
- 1,812
- References
- 173
- Citations by year
- 2026: 80 · 2025: 73 · 2024: 102 · 2023: 86 · 2022: 96 · 2021: 109 · 2020: 127 · 2019: 129 · 2018: 113 · 2017: 136 · 2016: 160 · 2015: 170 · 2014: 157 · 2013: 137 · 2012: 115
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug discovery strategies, phenotypic screening, target-based screening, molecular mechanisms of action, first-in-class drugs, new chemical entities, small molecule drugs, drug attrition, FDA-approved drugs
- MeSH terms
- Pharmacological Phenomena, Drug Industry, Drug Evaluation, Preclinical, Humans, United States, United States Food and Drug Administration, Drug Design, Drug Approval, Drug Discovery, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.